Satish Pillai, PhD
Professor
Laboratory Medicine
School of Medicine

Although the advent of Highly Active Antiretroviral Therapy (HAART) has dramatically decreased the morbidity and mortality associated with HIV-1 infection, there is a pronounced demand for alternative clinical management strategies due to frequent evolution of antiretroviral resistance, toxicity, and access constraints in resource-limited settings. My research is focused on identifying and characterizing novel host factors that act against HIV-1, by investigating the molecular determinants underlying the anti-HIV-1 activity of the antiviral cytokine interferon-alpha (IFN-a) in vivo. These host factors may serve as the foundations of future prophylactic, therapeutic and eradication strategies for HIV-1 infection.

Induction of IFN-a expression is a critical first step in the defense against a range of viral infections. The antiretroviral activity of the IFN-a cytokine was demonstrated in vitro almost immediately after the discovery of HIV-1, and includes inhibition of HIV-1 reverse transcription, viral assembly and virion release. Several clinical studies including our own report that IFN-a treatment acts against HIV-1 in vivo, and potently suppresses HIV-1 viremia in chronically-infected individuals. The precise molecular mechanisms underlying this suppressive activity in vivo, however, remain to be elucidated.

My laboratory uses a systems biology approach to decipher the antiretroviral effects of IFN-a in vivo, by studying host gene expression, viral production and viral evolution in HIV-1-infected individuals undergoing IFN-a therapy. Recent data generated by our group strongly suggest that IFN-a suppresses HIV-1 replication in chronically infected individuals by inducing intrinsic cellular inhibitors of retroviral replication known as host restriction factors. One of these factors, the cytidine deaminase APOBEC3, blocks HIV-1 infection by hypermutating the viral genome so it no longer encodes functional proteins that are necessary for viral replication. Another factor, the type 2 integral membrane protein BST-2/tetherin, blocks HIV-1 infection by restricting the release of fully formed progeny virions from infected cells. Our data warrant investigation into therapeutic strategies that specifically enhance the expression of these intrinsic immune factors in HIV-1-infected individuals. For a concise explanation of my latest research and its implications, please visit this new UCSF press release:

http://www.ucsf.edu/news/2012/02/11598/fighting-infections-old-drug-reveals-new-tricks

In addition to the my principal research projects involving IFN-a and host restriction factors, I participate as a bioinformaticist and phylogeneticist in a number of HIV/AIDS collaborations with researchers at the San Francisco VA Medical Center (SFVAMC), San Francisco General Hospital (SFGH) and the Gladstone Institute of Virology and Immunology (GIVI).

• Elevated Galectin-9 across the human brain correlates with HIV neuropathology and detrimental cognitive states.
  Journal of neurovirology 2023 Premeaux TA, Yeung ST, Pillai SK, Ndhlovu LC
• A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells.
  Research square 2023 Pillai S, Du L, Deiter F, Bouzidi M, Billaud JN, Graham S, Prerna D, Selvarajah S, Lingappa A, Michon M, Yu S, Paulvannan K, Lingappa V, Boushey H, Greenland J
• Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.
  AIDS (London, England) 2022 Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, Gibson EA, Kroetz DL, Martin J, Hecht F, Pilcher C, Martin M, Carrington M, Pillai S, Busch MP, Stone M, Levy CN, Huang ML, Roychoudhury P, Hladik F, …
• Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.
  Frontiers in immunology 2022 Yeung ST, Premeaux TA, Du L, Niki T, Pillai SK, Khanna KM, Ndhlovu LC
• Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.
  American journal of physiology. Lung cellular and molecular physiology 2022 Khanna K, Raymond WW, Jin J, Charbit AR, Gitlin I, Tang M, Werts AD, Barrett EG, Cox JM, Birch SM, Martinelli R, Sperber HS, Franz S, Duff T, Hoffmann M, Healy AM, Oscarson S, Pöhlmann S, Pillai SK, …
• Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation in Airway Epithelial Cells.
  bioRxiv : the preprint server for biology 2022 Du L, Bouzidi MS, Gala A, Deiter F, Billaud JN, Yeung ST, Dabral P, Jin J, Simmons G, Dossani Z, Niki T, Ndhlovu LC, Greenland JR, Pillai SK
• Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 Infection.
  The Journal of Immunology 2022 Stephen T Yeung, Thomas A Premeaux, Toshiro Niki, Satish K Pillai, Kamal M Khanna, Lishomwa C Ndhlovu
• IL10 trains macrophage profibrotic function after lung injury.
  American journal of physiology. Lung cellular and molecular physiology 2022 Bhattacharyya A, Boostanpour K, Bouzidi M, Magee L, Chen TY, Wolters R, Torre P, Pillai SK, Bhattacharya M
• Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro.
  bioRxiv : the preprint server for biology 2021 Khanna K, Raymond W, Jin J, Charbit AR, Gitlin I, Tang M, Werts AD, Barrett EG, Cox JM, Birch SM, Martinelli R, Sperber HS, Franz S, Pillai S, Healy AM, Duff T, Oscarson S, Hoffmann M, Pöhlmann S, …
• Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins.
  Cell reports 2021 Hiatt J, Cavero DA, McGregor MJ, Zheng W, Budzik JM, Roth TL, Haas KM, Wu D, Rathore U, Meyer-Franke A, Bouzidi MS, Shifrut E, Lee Y, Kumar VE, Dang EV, Gordon DE, Wojcechowskyj JA, Hultquist JF, …
• Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection.
  Mucosal immunology 2021 Egedal JH, Xie G, Packard TA, Laustsen A, Neidleman J, Georgiou K, Pillai SK, Greene WC, Jakobsen MR, Roan NR
• TCF-1 regulates HIV-specific CD8+ T cell expansion capacity.
  JCI insight 2021 Rutishauser RL, Deguit CDT, Hiatt J, Blaeschke F, Roth TL, Wang L, Raymond KA, Starke CE, Mudd JC, Chen W, Smullin C, Matus-Nicodemos R, Hoh R, Krone M, Hecht FM, Pilcher CD, Martin JN, Koup RA, Douek…
• Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo.
  Journal of virology 2021 Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber HS, Hull PA, Montano M, Migueles SA, Rosenthal D, Hogan LE, Johnson JR, Packard TA, Grimmett ZW, Herzig E, Besnard E, Nekorchuk M, Hsiao F,…
• SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
  Nature communications 2020 Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, Prostko J, Rodgers M, Coller K, Pearce S, Franz S, Du L, Stone M, Pillai SK, Sotomayor-Gonzalez A, Servellita V, Martin CSS, Granados A, …
• μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020 Sperber HS, Togarrati PP, Raymond KA, Bouzidi MS, Gilfanova R, Gutierrez AG, Muench MO, Pillai SK
• Seminal Plasma-Derived Extracellular-Vesicle Fractions from HIV-Infected Men Exhibit Unique MicroRNA Signatures and Induce a Proinflammatory Response in Cells Isolated from the Female Reproductive Tract.
  Journal of virology 2020 Marques de Menezes EG, Jang K, George AF, Nyegaard M, Neidleman J, Inglis HC, Danesh A, Deng X, Afshari A, Kim YH, Billaud JN, Marson K, Pilcher CD, Pillai SK, Norris PJ, Roan NR
• FOXO1 promotes HIV latency by suppressing ER stress in T cells.
  Nature microbiology 2020 Vallejo-Gracia A, Chen IP, Perrone R, Besnard E, Boehm D, Battivelli E, Tezil T, Krey K, Raymond KA, Hull PA, Walter M, Habrylo I, Cruz A, Deeks S, Pillai S, Verdin E, Ott M
• SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.
  medRxiv : the preprint server for health sciences 2020 Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, Prostko J, Rodgers M, Coller K, Pearce S, Franz S, Du L, Stone M, Pillai SK, Sotomayor-Gonzalez A, Servellita V, Martin CSS, Granados A, …
• OP 1.1 Expression profiling of HIV latently-infected cells using nanostring and mass cytometry.
  Journal of virus eradication 2019 H. Sperber, T. Ma, N.R. Roan, S.K. Pillai
• PP 2.6 µ-Lat: a high-throughput humanised mouse model of latent HIV infection.
  Journal of virus eradication 2019 H. Sperber, P.P. Togarrati, K. Raymond, M.S. Bouzidi, R. Gilfanova, M.O. Muench, S.K. Pillai
• Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency.
  PLoS pathogens 2019 Li Z, Wu J, Chavez L, Hoh R, Deeks SG, Pillai SK, Zhou Q
• Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.
  Journal of neurovirology 2018 Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gisslén M, Price RW, Valcour V, Ndhlovu LC
• Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function.
  Nature communications 2018 Laustsen A, Bak RO, Krapp C, Kjær L, Egedahl JH, Petersen CC, Pillai S, Tang HQ, Uldbjerg N, Porteus M, Roan NR, Nyegaard M, Denton PW, Jakobsen MR
• Granulocyte-Derived Extracellular Vesicles Activate Monocytes and Are Associated With Mortality in Intensive Care Unit Patients.
  Frontiers in immunology 2018 Danesh A, Inglis HC, Abdel-Mohsen M, Deng X, Adelman A, Schechtman KB, Heitman JW, Vilardi R, Shah A, Keating SM, Cohen MJ, Jacobs ES, Pillai SK, Lacroix J, Spinella PC, Norris PJ
• Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells.
  eLife 2018 Battivelli E, Dahabieh MS, Abdel-Mohsen M, Svensson JP, Tojal Da Silva I, Cohn LB, Gramatica A, Deeks S, Greene WC, Pillai SK, Verdin E
• Granulocyte-derived extracellular vesicles activate monocytes and are associated with mortality in ICU patients.
  The Journal of Immunology 2018 Philip Norris, Heather C. Inglis, Mohamed Abdel-Mohsen, Xutao Deng, Avril Adelman, Kenneth B. Schechtman, Sheila Marie Keating, Mitchell J. Cohen, Evan S. Jacobs, Satish Pillai, Jacques Lacroix, …
• D-106 Chromatin Functional States Correlate with the Reversal of Latently HIV-1 Infected Primary CD4+ T cells.
  JAIDS Journal of Acquired Immune Deficiency Syndromes 2018 Emilie Battivelli, Matthew S. Dahabieh, Mohamed Abdel-Mohsen, J. Peter Svensson, Israel Tojal Da Silva, Lilian B. Cohn, Andrea Gramatica, Steven Deeks, Warner Greene, Satish K. Pillai, Eric Verdin
• Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.
  Journal of the International AIDS Society 2017 Bangirana P, Ruel TD, Boivin MJ, Pillai SK, Giron LB, Sikorskii A, Banik A, Achan J
• The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.
  Mucosal immunology 2017 Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A, Keshavarzian A, Deng X, Olesen R, Petersen AM, Benfield T, Østergaard L, Rasmussen TA, …
• HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.
  The Journal of infectious diseases 2017 Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht F, Deeks SG, Pillai SK, Busch MP
• OA2-3 Small-molecule chemotherapeutic drugs reactivate HIV-1 via non-canonical pathways and modulate CD8 T cell response.
  Journal of virus eradication 2017 I. Munoz-Arias, E. Hanhauser, L. Hogan, M.A. Mohsen, Kristen Hobbs, C. Thanh, E. Gibson, S.G. Deeks, S.K. Pillai, T.J. Henrich
• Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017 Vibholm L, Schleimann MH, Højen JF, Benfield T, Offersen R, Rasmussen K, Olesen R, Dige A, Agnholt J, Grau J, Buzon M, Wittig B, Lichterfeld M, Petersen AM, Deng X, Abdel-Mohsen M, Pillai SK, Rutsaert…
• Identification and characterization of a rich population of CD34+ mesenchymal stem/stromal cells in human parotid, sublingual and submandibular glands.
  Scientific reports 2017 Togarrati PP, Sasaki RT, Abdel-Mohsen M, Dinglasan N, Deng X, Desai S, Emmerson E, Yee E, Ryan WR, da Silva MCP, Knox SM, Pillai SK, Muench MO
• Signature of the Sleeper Cell: A Biomarker of HIV Latency Revealed.
  Trends in immunology 2017 Pillai SK, Deeks SG
• Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies.
  The Journal of infectious diseases 2017 Henrich TJ, Deeks SG, Pillai SK
• Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression.
  Journal of virology 2017 Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, Martin JN, Zhang J, Kaidarova Z, Deng X, Wu S, Anastos K, Crystal H, Villacres MC, Young M, Greenblatt RM, Landay AL, Gange SJ, …
• Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.
  PLoS pathogens 2016 Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK
• Human galectin-9 is a potent mediator of HIV transcription and reactivation.
  Journal of virus eradication 2015 M. Abdel-Mohsen, L. Chavez, G.M. Chew, X. Deng, A. Danesh, S. Keating, R. Hoh, S.G. Deeks, L.C. Ndhlovu, S.K. Pillai
• PP 3.19 Evidence of ongoing HIV replication during suppressive antiretroviral therapy.
  Journal of virus eradication 2015 L. Bertoni Giron, S. Tenore, M.C. Araripe Sucupira, L.M. Janini, S. Pillai, R. Sobhie Diaz
• TIMP3 Attenuates the Loss of Neural Stem Cells, Mature Neurons and Neurocognitive Dysfunction in Traumatic Brain Injury.
  Stem cells (Dayton, Ohio) 2015 Gibb SL, Zhao Y, Potter D, Hylin MJ, Bruhn R, Baimukanova G, Zhao J, Xue H, Abdel-Mohsen M, Pillai SK, Moore AN, Johnson EM, Cox CS, Dash PK, Pati S
• Antiviral gene expression in psoriasis.
  Journal of the European Academy of Dermatology and Venereology : JEADV 2015 Raposo RA, Gupta R, Abdel-Mohsen M, Dimon M, Debbaneh M, Jiang W, York VA, Leadabrand KS, Brown G, Malakouti M, Arron S, Kuebler PJ, Wu JJ, Pillai SK, Nixon DF, Liao W
• Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
  AIDS (London, England) 2015 Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK
• Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.
  PloS one 2014 Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs ES, Rauch A, Ledergerber B, Norris PJ, Günthard HF, Wong JK, Pillai SK
• Evolutionary History of the Proviruses HERV-K 113 and HERV-K 115.
  eLS 2014 Keith E Garrison, Douglas F Nixon, Satish K Pillai, Aashish R Jha
• Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo.
  Journal of virology 2014 Raposo RA, Abdel-Mohsen M, Deng X, Hecht FM, Pilcher CD, Pillai SK, Nixon DF
• Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
  The Journal of infectious diseases 2014 Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham LR, Pilcher CD, Hecht FM, Sinclair E, Liegler T, Richman DD, Deeks SG, Pillai SK
• Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.
  Journal of virology 2013 Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK
• Expression profile of host restriction factors in HIV-1 elite controllers.
  Retrovirology 2013 Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem Hel-D, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK
• Hematopoietic cell transplantation and HIV cure: where we are and what next?
  Blood 2013 Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner N, NHLBI AIDS Blood Session Working Group
• Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells.
  Journal of virology 2013 Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori DC, Nixon DF, Pillai SK
• Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals.
  Journal of leukocyte biology 2013 Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, Liao W, Pillai SK, Nixon DF
• Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.
  PLoS pathogens 2013 Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, …
• Host correlates distinguish low-risk and high-risk HIV-1 disease progression in HLA-B*5701 individuals (P6169).
  The Journal of Immunology 2013 Andre Raposo, Mohamed Abdel-Mohsen, Frederick Hecht, Christopher Pilcher, Satish Pillai, Douglas Nixon
• Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
  Proceedings of the National Academy of Sciences of the United States of America 2012 Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong …
• Human endogenous retrovirus K106 (HERV-K106) was infectious after the emergence of anatomically modern humans.
  PloS one 2011 Jha AR, Nixon DF, Rosenberg MG, Martin JN, Deeks SG, Hudson RR, Garrison KE, Pillai SK
• BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action.
  Virology 2011 Skasko M, Tokarev A, Chen CC, Fischer WB, Pillai SK, Guatelli J
• Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection.
  AIDS (London, England) 2010 Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L
• In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.
  PLoS pathogens 2010 Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, Ignacio CC, Russell T, Pillai SK, Looney DJ, Dandekar S
• Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.
  AIDS (London, England) 2010 Manosuthi W, Butler DM, Pérez-Santiago J, Poon AF, Pillai SK, Mehta SR, Pacold ME, Richman DD, Pond SK, Smith DM
• Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens.
  Molecular biology and evolution 2009 Jha AR, Pillai SK, York VA, Sharp ER, Storm EC, Wachter DJ, Martin JN, Deeks SG, Rosenberg MG, Nixon DF, Garrison KE
• Association between specific HIV-1 Env traits and virologic control in vivo.
  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2009 Joos B, Rieder P, Fischer M, Kuster H, Rusert P, Trkola A, Pillai SK, Wong JK, Weber R, Günthard HF
• Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.
  Virology 2009 Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Günthard H, Richman D, Rice AP, Daar E, Little S, Wong JK
• Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations.
  Virology 2008 Smith DM, Zárate S, Shao H, Pillai SK, Letendre SL, Wong JK, Richman DD, Frost SD, Ellis RJ, HNRC Group
• HIV rebounds from latently infected cells, rather than from continuing low-level replication.
  Proceedings of the National Academy of Sciences of the United States of America 2008 Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, Hirschel B, Weber R, Trkola A, Günthard HF, Swiss HIV Cohort Study
• Estimating selection pressures on HIV-1 using phylogenetic likelihood models.
  Statistics in medicine 2008 Kosakovsky Pond SL, Poon AF, Zárate S, Smith DM, Little SJ, Pillai SK, Ellis RJ, Wong JK, Leigh Brown AJ, Richman DD, Frost SD
• Inferring HIV transmission dynamics from phylogenetic sequence relationships.
  PLoS medicine 2008 Pilcher CD, Wong JK, Pillai SK
• Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
  Retrovirology 2008 Pillai SK, Wong JK, Barbour JD
• Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.
  AIDS (London, England) 2007 Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR
• Rational peptide selection to detect human immunodeficiency virus type 1-specific T-cell responses under resource-limited conditions.
  Clinical and vaccine immunology : CVI 2007 Willberg CB, Pillai SK, Sharp ER, Rosenberg MG, Agudelo JD, Barbour JD, Nixon DF
• Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1.
  Journal of virology 2007 Noviello CM, Pond SL, Lewis MJ, Richman DD, Pillai SK, Yang OO, Little SJ, Smith DM, Guatelli JC
• Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
  Virology 2006 Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD
• Genetic attributes of cerebrospinal fluid-derived HIV-1 env.
  Brain : a journal of neurology 2006 Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, Günthard HF, Grant I, Marcotte TD, McCutchan JA, Richman DD, Wong JK
• Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif.
  Journal of virology 2006 Coleman SH, Madrid R, Van Damme N, Mitchell RS, Bouchet J, Servant C, Pillai S, Benichou S, Guatelli JC
• Codon volatility does not reflect selective pressure on the HIV-1 genome.
  Virology 2005 Pillai SK, Kosakovsky Pond SL, Woelk CH, Richman DD, Smith DM
• Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
  Journal of virology 2005 Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Günthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, Marquie-Beck J, Durelle J, Grant I, Richman DD, Marcotte T, McCutchan JA, Ellis RJ, Wong…
• Semen-specific genetic characteristics of human immunodeficiency virus type 1 env.
  Journal of virology 2005 Pillai SK, Good B, Pond SK, Wong JK, Strain MC, Richman DD, Smith DM
• Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
  Nature structural & molecular biology 2004 Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR
• Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea.
  Journal of virology 2003 Kunstman KJ, Puffer B, Korber BT, Kuiken C, Smith UR, Kunstman J, Stanton J, Agy M, Shibata R, Yoder AD, Pillai S, Doms RW, Marx P, Wolinsky SM
• Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations.
  Journal of immunology (Baltimore, Md. : 1950) 2003 Ali A, Pillai S, Ng H, Lubong R, Richman DD, Jamieson BD, Ding Y, McElrath MJ, Guatelli JC, Yang OO
• Sequence Note: A New Perspective on V3 Phenotype Prediction.
  AIDS Research and Human Retroviruses 2003 Satish Pillai, Benjamin Good, Douglas Richman, Jacques Corbeil
• A new perspective on V3 phenotype prediction.
  AIDS research and human retroviruses 2003 Pillai S, Good B, Richman D, Corbeil J
• The sequential introduction of HIV-1 subtype B and CRF01AE in Singapore by sexual transmission: accelerated V3 region evolution in a subpopulation of Asian CRF01 viruses.
  Virology 2002 Kalish ML, Korber BT, Pillai S, Robbins KE, Leo YS, Saekhou A, Verghese I, Gerrish P, Goh CL, Lupo D, Tan BH, Brown TM, Chan R
• Synergism in the Oviposition Behavior of Plutella xylostella: Sinigrin and Wax Compounds.
  Journal of Insect Behavior 1999 Joseph L. Spencer, Satish Pillai, Elizabeth A. Bernays
• Neonate Plutella xylostella Responses to Surface Wax Components of a Resistant Cabbage (Brassica oleracea).
  Journal of Chemical Ecology 1998 Sanford D. Eigenbrode, Satish K. Pillai